Standard Biotools (LAB) Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Revenue data on file, last reported at $21.1 million in Q1 2026.

• Quarterly Revenue rose 4.57% year-over-year to $21.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.3 million (down 3.71% YoY) and the FY2025 annual result came in at $85.3 million, down 6.24% from the prior year.
• Revenue slipped to $21.1 million in Q1 2026 per LAB's latest filing, from $23.8 million in the prior quarter.
• Across five years, Revenue topped out at $45.5 million in Q1 2024 and bottomed at $18.8 million in Q2 2022.
• The 5-year median for Revenue is $24.8 million (2024), against an average of $25.0 million.
• The widest annual swing landed in 2024, when Revenue jumped 81.3%; it then sank 55.6% in 2025.
• Tracing LAB's Revenue over 5 years: stood at $27.0 million in 2022, then increased by 4.32% to $28.2 million in 2023, then declined by 12.1% to $24.8 million in 2024, then decreased by 3.96% to $23.8 million in 2025, then slipped by 11.13% to $21.1 million in 2026.
• Per Business Quant, the three latest LAB Revenue figures stand at $21.1 million (Q1 2026), $23.8 million (Q4 2025), and $19.6 million (Q3 2025).

Peer Comparison